Professeur Philippe NGUYEN

Professeur Philippe NGUYEN

Professeur des Universités - Praticien Hospitalier

Spécialités

  • Hématologie

Contactez-moi

Activités

Médecin spécialiste en maladies du sang : maladies hémorragiques et thrombotiques

Médecin spécialiste en Hématologie Biologique

Responsable du Centre Régional du Traitement de l’Hémophilie de Reims-Champagne Ardenne (certification européenne EUHANET)

Coordonnateur du Centre de Compétence Multi site Grand Est

Responsable de la structure Génétique-Hématologie-Immunologie-Biologie de la Reproduction de Pôle de Biologie

Activité de consultation

Participation aux RCP Hémostase et Thrombose du CHU et  Cancer et Thrombose de l’Institut Jean Godinot

Directeur d’Unité de recherche : Université de Reims : Hémostase et Remodelage Vasculaire post-Ischémie : HERVI EA 3801

 

Parcours universitaire

Etude de médecine (1976-1981) et Internat en Médecine (1981-1984)

Research Fellowship Canada (1984-1985)

Doctorat en Médecine (1986)

CES D’Hématologie, Certificat d’Hématologie Spécialisée Paris VII (1983)

CES d’Immunologie (1984)

Fundamentals of Clinical Epidemiology, Mc University Hamilton Canada (1985)

DEA de Biologie Universités Reims Nancy Strasbourg (1988)

Doctorat d’Université (1998)

Diplôme d’Université en Thérapie Cellulaire Paris VII (2000)

Habilitation à Diriger des Recherches (2000)

Professeur des Universités section CNU 47.01 Hématologie-Transfusion (2001)

Direction d’Unité de Recherche : depuis 2008

 

Membre de sociétés savantes

Société Française d’Hématologie (SFH)

Groupe Français d’Hémostase et Thrombose (GFHT)

Coordination Médicale pour l’Etude et le traitement des Maladies Hémorragiques constitutionnelles (COMETH)

Groupe Interdisciplinaire d’Hémostase Péri opératoire (GIHP)

American Society of Haematology (ASH)

International Society of Thrombosis and Haemostasis (ISTH)

 

Recherches en cours

Caractérisation de produits de thérapie cellulaire (étude ancillaire du PHRC National BALI et projet financé par le CPER)

Mesure de la génération de Thrombine : évaluation de l’instrument GENESIA (partenariat industriel Diagnostica Stago (France)

Etudes cliniques en Hémophilie

Thrombopathie et Hémodialyse (AOL)

Etudes fondamentales en lien avec l’EA3801 HERVI et les équipes de la SFR Cap Santé

 

Publications

Articles Comité de Lecture (ACL)

ACL1    Leclerc J, Geerts W, Panju A, Nguyen P, Hirsh J. Management of antithrombin III deficiency during pregnancy without administration of antithrombin III. Thromb Res 1986; 41: 567-73. Impact factor 2.44 rang C

ACL2     Fernandez F, Nguyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-5. Impact factor 2.44 rang C

ACL3     Nguyen P, Adjizian JC, Toupance O, Jolly D, Brissart A, Petitfrère E. Rheology of hemodialyzed patients: erythrocytic populations study. Effect of a low molecular weight heparin (K2165). Clin Haemorheol 1988; 8: 415-23.

ACL4     Van Ryn-Mc Kenna J, Nguyen P, Ofosu FA, Hirsh J, Buchanan MR. The effects of DDAVP on heparin-induced bleeding. Thromb Haemorrh Disorders 1990; 1: 23-7.

ACL5     Nguyen P, Jolly D, Devie B, Marcus C, Adjizian JC, Menanteau B, Potron G.  Influence des produits de contraste sur l’agrégation et la déformabilité érythrocytaire in vitro. J Mal Vasc 1990 ; 15 : 347-52. Impact factor 0.543 rang E
 
ACL6     Nguyen P, Jolly D, Devie B, Marcus C, Adjizian JC, Menanteau B, Potron G. Influence des produits de contraste sur l’agrégation érythrocytaire : une étude ex vivo. J Mal Vasc 1991 ; 16 : 53-7. Impact factor 0.543 rang E

ACL7     Petitfrère E, Nguyen P, Mailliot JL, Culioli-Pickel B, Potron G. Altération de la membrane érythrocytaire : conséquence de l’activation des neutrophiles. J Mal Vasc 1991 ; 16 : 275-8. Impact factor 0.543 rang E

ACL8    Metz D, Nguyen P, Chapoutot L, Graciet J, Taupin JM, Grentziger A, Elaerts J, Bajolet A. Embolie pulmonaire massive révélant une thrombopénie induite par héparine de bas poids moléculaire : succès thérapeutique d’une prostacycline. Ann Cardiol Angiol 1991 ; 40 : 619-21. Impact factor 0.278 rang E

ACL9     Potron G, Nguyen P. Temps de lyse des euglobulines. STV 1992 ; 4 : 133-5. Impact factor 0.029

ACL10     Potron G, Petitfrère E, Nguyen P. Platelet activating factor and ischemia (Review article). Clin Haemorheol 1993; 13: 155-76.

ACL11     Nguyen P, Toupance O, Chanard J, Potron G. Variations of protein C in uremic    hemodialyzed patients. Thromb Res 1993; 69: 509-18. Impact factor 2.44 rang C

ACL12     Lartigue B, Barré J, Nguyen P, Potron G. Comparative study of hydroxyethylstarch 200/0.62 versus dextran 60 in hemodilution during total hip replacement: influences of hemorheological parameters. Clin Haemorheol 1993; 13: 779-89.

ACL13     Toupance O, Nguyen P, Brandt B, Dion JJ, Potron G, Chanard J. Prevention of   vascular thrombosis by human purified protein C concentrate in a patient with familial PC deficiency undergoing renal transplantation. Transpl Int 1994; 7: 144-8 [letter]. Impact factor 2.921 rang B

ACL14     Nguyen P, Raynaud J, Pouzol P, Munzer M, Richard O, François P. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 1994; 158: 646-9. Impact factor 1.879 rang C

ACL15     Potron G, Nguyen P, Pignon B. Fibrinogen, as an arterial risk in clinical practice. Clin Haemorheol 1994; 14: 739-67.

ACL16     Potron G, Jolly D, Nguyen P, Mailliot JL, Pignon B. Approach to erythrocytic aggregation through erythrocyte sedimentation rate : application of a statistical model in pathology. Nouv Rev Fr Hématol 1994 ; 36 : 241-7.

ACL17     Nguyen P, Lecompte T and Groupe d’Etude sur l’Hémostase et la Thrombose de la  Société Française d’Hématologie. Heparin-induced thrombocytopenia: a survey of tests employed and attitudes in haematology laboratories. Nouv Rev Fr Hématol 1994; 36: 353-7.

ACL18     Favier R, Nguyen P, de Moerloose P. Pour ou contre un bilan d’hémostase pré-opératoire chez un enfant sain ? (Editorial) Arch Pédiatr 1994 ; 1 : 11-3. Impact factor 0.298 rang E

ACL19     Lartigue B, Barré J, Nguyen P, Potron G. Modifications hémorhéologiques au cours des hémodilutions pré-opératoires des prothèses totales de hanche : étude randomisée comparant un hydroxyéthylamidon 200 000/0.62 et un dextran 60 000. J Mal Vasc 1994 ; 19 : 27-31. Impact factor 0.543 rang E.
ACL20     Pignon B, Jolly D, Potron G, Lartigue B, Vilque JP, Nguyen P, Etienne JC, Stolz JF. Erythrocyte aggregation – determination of normal values: influence of age, sex, hormonal state, oestroprogestative treatment, hematological parameters and cigarette smoking. Nouv Rev Fr Hématol 1994; 36: 431-9.

ACL21     Nguyen P, Petitfrère E, Potron G. Mechanism of the platelet aggregation induced by the activated neutrophils and inhibitory effect of specific PAF receptor antagonists. Thromb Res 1995; 78: 33-42. Impact factor 2.44 rang C

ACL22     Nguyen P, Cornillet P, Potron G. A new case of severe hemophilia B Leiden associated with a G to C mutation at position – 6 of the factor IX promoter. Am J Hematol 1995; 49: 259-60 [letter]. Impact factor 4.671 rang B

ACL23     Nguyen P, Droullé C, Potron G. Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 804-5 [letter]. Impact factor 5.044 rang B

ACL24     Nguyen P, Germain ML, Sume L, Choisy H. Imputability of heparin in heparin induced thrombocytopenia   a 10 year experience of the Centre Régional de Pharmacovigilance of Reims-Champagne-Ardenne. Nouv Rev Fr Hématol 1995; 37: 307-12.

ACL25     Stieljes N, Sultan Y, Rothschild C, Torchet MF, Laurian Y, Navarro R, Fressinaud E,  Parquet Gernez A, Fonlupt J, Berthier AM, and the French Hemophilia Study Group. Long term survival of HIV-infected patients with haemophilia. Haemophilia 1995; 1: 33-6. Impact factor 2.597 rang D

ACL26     Nguyen P, Durlach V, Leutenegger M, Guenounou M, Potron G. Explosion respiratoire des polynucléaires neutrophiles et profil des cytokines chez le diabétique non insulinodépendant. J Mal Vasc 1995 ; 20 : 102-5. Impact factor 0.543 rang E

ACL27     Potron G, Nguyen P. Traitement des thromboses veineuses profondes à domicile. Ann Cardiol Angéiol 1995 ; 4444 : 448-53. Impact factor 0.278 rang E

ACL28     Potron G, Nguyen P, Pignon G. Le fibrinogène : facteur de risque (Revue). J Mal Vasc 1996 ; 21 : 126-32. Impact factor 0.543 rang E

ACL29     Estève E, Roger M, Nguyen P, Kalis B. Cas pour diagnostic : ulcérations cutanées dues à l’Hydréa®. Ann Dermatol Venerol 1996 ; 123 : 271-2. Impact factor 0.716 rang E

ACL30     Nguyen P, Hézard N, Cornillet P, Potron G. ROC curve to evaluate the performance of “ clotting ” methods for Factor V Leiden. Br J Haematol 1997; 96: 872-3 [letter]. Impact factor 4.941 rang B

ACL31     Hézard N, Cornillet P, Droullé C, Gillot L, Potron G, Nguyen P. Factor V Leiden : detection in whole blood by ASA PCR using an additional mismatch in antepenultimate position. Thromb Res 1997; 88: 59-66. Impact factor 2.44 rang C

ACL32     Négrier C, Goudemand J, Sultan Y, Bertrand M, Rotschild C, Lauroua P and the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9. Impact factor 5.044  rang B

ACL33     Hézard N, Cornillet P, Vallade A, Nguyen P. Detection of Factor V Leiden using ASO (Allele Specific Oligonucleotide). Thromb Haemost 1997; 78: 1296 [letter]. Impact factor 5.044 rang B

ACL34     Lévy S, Diébold MD, Nguyen P, Lirzin P, Thiéfin G. Nodular regenerative hyperplasia of the liver associated with a Factor V Leiden mutation. Eur J Gastroenterol and Hepatol 1997; 10: 721 [letter]. Impact factor 1.757 rang D

ACL35     Broussas M, Cornillet-Lefebvre P, Potron G, Nguyen P. Monocyte and Haemostasis. Hematology 1998; 3: 77-87. Impact factor 1.487 rang D

ACL36     Hézard N, Metz D, Potron G, Nazeyrollas P, Maes D, Droullé C, Mulpas MC, Elaerts J, Nguyen P. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA) : assessment of three bedside coagulation monitors. Thromb Haemost 1998; 80 : 865-6 [letter]. Impact factor 5.044 rang B

ACL37     Hézard N, Cornillet-Lefebvre P, Gillot L, Potron G, Nguyen P. Multiplex ASA PCR for a simultaneous determination of Factor V Leiden gene, G-A 20210 prothrombin gene and C-T 677 MTHFR gene mutations. Thromb Haemost 1998; 79: 1054-5 [letter]. Impact factor 5.044 rang B

ACL38     Nguyen P. Diagnostic et surveillance biologique des thrombopénies induites par l’héparine (Revue). Presse Médicale 1998 ; 27 : S13-17. Impact factor 0.667

ACL39     Verdy E, Nguyen P. Thrombopénie induite par l’héparine (Revue). Le praticien en anesthésie réanimation 1998 ; 2 : 208-11.

ACL40     Nguyen P, Broussas M, Hézard N, Cornillet P, Potron G. Les modificateurs de  l’hémostase. J Mal Vasc 1998 ; 23 : 119-24. Impact factor 0.543 rang E

ACL41     Nguyen P. Diagnostic et surveillance biologique des thrombopénies induites par l’héparine. Presse Med 1998 ; 27S13-17. Impact factor 0.667 rang D

ACL42     Nguyen P, de Maistre E, Cornillet-Lefebvre P, Regnault V, Lecompte T. Heparin-induced thrombocytopenia in France, 1980-1998. Semin Thromb Haemost 1999; 25: 9-15. Impact factor 4.524 rang B

ACL43     Hézard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphard S, Droullé C, Elaerts J, Potron G. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999; 81: 869-73. Impact factor 5.044 rang B

ACL44     Nguyen P, Broussas M, Cornillet-Lefebvre P, Potron G. Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukopheresis and elutriation. Response of nonadherent cells to lipopolysaccharide. Transfusion 1999; 39: 975-82. Impact factor 3.217 rang C

ACL45     Nguyen P, Rémy MG, Potron G. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins. Haemostasis 1999; 29: 301-9.

ACL46     Broussas M, Cornillet-Lefebvre P, Potron G, Nguyen P. Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J Leuk Biol 1999; 66: 495-501. Impact factor 4.992 rang B

ACL47     Nguyen P, Broussas M, Bertin E, Simon G, Hézard N, Potron G. Mesure de l’activation monocytaire : perspectives d’application clinique dans l’exploration du patient diabétique. J Mal Vasc 1999 ; 24 : 275-80. Impact factor 0.543 rang E

ACL48     Hézard N, Metz D, Nazeyrollas P, Droullé C, Elaerts J, Potron G., Nguyen P. Use of PFA-100TM apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000; 83: 540-4. Impact factor 5.044 rang B

ACL49     Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger M. Plasma levels of tumor necrosis factor-alpha (TNF-?) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes and Metabolism 2000; 26: 178-82. Impact factor 2.411 rang D
    
ACL50     Broussas M, Cornillet-Lefebvre P, Bernard J, Adjizian JC, Potron G, Nguyen P. Separation of dendritic cells from highly purified human monocytes by counterflow centrifugation induces tissue factor expression. Transfusion 2000; 40: 1088-94. Impact factor 3.217 rang C

ACL51     Garnotel R, Rittié L, Poitevin S, Monboisse JC, Nguyen P, Maquart FX, Randoux A, Gillery P. Human blood monocytes interact with type I collagen through ?x?2 integrin (CD11c-CD18, gp 150-95). J Immunol 2000; 164: 5928-34. Impact factor 5.788 rang B

ACL52    Nguyen P, Denninger MH, Fressinaud E, Huisse MG, Lasne D, Lecompte T, Nurden P, Veyradier A. Forum biologique : Le PFA 100™ remplacera-t-il le temps de saignement ? Hématologie 2000 ; 6 : 93-102.

ACL53     Latger-Canard V, Regnault V, Dumas D, Nguyen P, Lecompte T, Stoltz JF. Mesure des récepteurs d’adhérence du polynucléaire neutrophile : influence des paramètres pré-analytiques. J Mal Vasc 2000 ; 25 : 181-6. Impact factor 0.543 rang E

ACL54     Hézard N, Metz D, Garnotel R, Droullé C, Potron G, Nguyen P. Interactions leucoplaquettaires au cours de l’insuffisance coronarienne. Physiopathologie, pertinence clinique, modulation pharmacologique. J Mal Vasc 2000 ; 25 : 343-8. Impact factor 0.543 rang E

ACL55    Lecompte T, Ferrari E, Nguyen P, de Moerloose P, Samama CM. Médicaments inhibiteurs des fonctions plaquettaires. STV 2000 ; 12 ; n° spécial : 3-11. Impact factor 0.029

ACL56     Boneu B, Potron G, Gruel Y, Nguyen P, Aiach M. Utilisation des héparines en pratique médicale courante. STV 2000 ; 12 : n° spécial : 12-25. Impact factor 0.029

ACL57     Hézard N, Metz D, Garnotel R, Droullé C, Potron G, Nguyen P. Interactions leucoplaquettaires au cours de l’insuffisance coronarienne. J Mal Vasc 2000 ; 25 : 343-8. Impact factor 0.543 rang E

ACL58     Hézard N, Metz D, Tassan-Magina S, Potron G, Nguyen P. Unexpected flow cytometric results with two small GPIIb/IIIa blockers : eptifibatide and tirofiban. Thromb Haemost 2001; 85: 561-2 [letter]. Impact factor 5.044 rang B

ACL59     Nguyen P, Hézard N, Potron G, Metz D. Surveillance biologique des traitements par les anti-GPIIb/IIIa : tests possibles, surveillance de l’héparinothérapie concomitante. STV 2001 ; 13 : 408-416. Impact factor 0.029

ACL60     Broussas M, Cornillet-Lefebvre P, Potron G, Nguyen P. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of A 3 adenosine receptor Thromb Haemost  2002 ; 88 : 123-30. Impact factor 5.044 rang B

ACL61     Hézard N, Metz D, Nazeyrollas P, Droullé C, Potron G, Nguyen P. PFA-100™ and flow cytometry : can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty ? Thromb Res 2003; 108: 43-7. Impact factor 2.44 rang C

ACL62     Regnault V, de Maistre E, Carteaux J-P, Gruel Y, Nguyen P, Tardy B, Lecompte T. Platelet activation induced by human antibodies to interleukin-8. Blood 2003; 101: 1419-21. Impact factor 9.898 rang A

ACL63     Gruel Y, Pouplard C, Nguyen P, Borg J-Y, Derlon A, Juhan-Vague I, Regnault V, Samama M and the French HIT study group. Biological and clinical features of low molecular weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121: 786-92. Impact factor 4.941 rang B

ACL64     Hézard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P. Unexpected Persistence of Impaired Platelet Function beyond the Neonatal Period : a Flow Cytometric Study in Neonates, Infants and Older Children. Thromb Haemost 2003; 90: 116-23. Impact factor 5.044 rang B

ACL65    Goudemand J, Caron C, Dreyfus M, Sié P. for the Haemostasis Standardization Group of the Groupe d’Etude Hémostase et Thrombose. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagulation and Fibrinolysis 2003; 14: 505-11. Impact factor 1.238 rang E

ACL66     Blanloeil Y, en collaboration avec le Groupe d’Etude Hémostase et Thrombose de la Société Française d’Hématologie, la Société Française de Cardiologie et la Société de Réanimation de Langue Française. Thrombopénie induite par l’héparine. Conférence d’experts 2002. STV 2003 ; 15 : 315-25. Impact factor 0.029

ACL67     Nguyen P, Hézard N, Daliphard S. Explorations de la fonction plaquettaire par cytométrie en flux. Hématologie 2003 ; 9 : 367-78.

ACL68     Touré F, Lavaud S, Mohajer M, Lavaud F, Canivet E, Nguyen P, Chanard J, Rieu P. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis. Kidney Int 2004; 65: 654-60. Impact factor 6.606 rang A

ACL69     Bouaziz L, Hézard N, Touhami M, Potron G, N'siri B, Nguyen P. Allelic Frequency of the Factor V Leiden Mutation and of the Prothrombin Gene 20210A Mutation in Healthy Tunisian Population. Thromb Haemost  2004; 91: 824-5. Impact factor 5.044 rang B

ACL70     N. Hézard, V. Jallu, R. Garnotel, C. Kaplan, P. Nguyen. DDAVP infusion can modify VASP phosphorylation in human platelets. JTH 2004; 2: 672-3. Impact factor 5.731 rang A

ACL71     Thrombopénie induite par l’héparine. Conférence d’experts – 2002. Texte court. En collaboration avec le Groupe d’Etude Hémostase et Thrombose de la Société Française d’Hématologie, la Société Française de Cardiologie et la Société de Réanimation de Langue Française. Hématologie 2004 ; 10 : 313-23.

ACL 72     Pignon B, Guillaume N, Capiod JC, Nguyen P, Lefrère JJ. Thérapie cellulaire à visée angiogénique dans les pathologies ischémiques. Hématologie 2004 ; 10 : 146-57.

ACL73     Nguyen P. Le surdosage à l’héparine. STV  Urgences vasculaires 2004 ; 16 : 263-7. Impact factor 0.029

ACL74     Mechiche H, Cornillet-Lefebvre P, Nguyen P. A subpopulation of human B lymphocytes can express a functional Tissue Factor in response to PMA. Thromb Haemost 2005; 94: 146-54. Impact factor 5.044 rang B

ACL75     Hézard N, Metz D, Garnotel R, Simon G, Macé C, Koebel P, Nguyen P. Platelet VASP phosphorylation assessement in clopidogrel-treated patients: Lack of agreement between Western blot and flow cytometry. Platelets 2005; 16(8) : 474-81. Impact factor 2.188 rang D

ACL76     Paysant J, Soria C, Cornillet-Lefebvre P, Nguyen P, Lenormand B, Mishal Z, Vannier J.P, Vasse M. Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitor. Br J Haematol 2005; 131: 356-65. Impact factor 4.941 rang B

ACL77     Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini G, Gillot L, Ifrah N, Nguyen P, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukaemia is not due to p110 delta mutations. Leukemia 2006; 20:374-6. (2006: Impact factor 6.146) Impact factor 9.561rang A

ACL78     Hézard N, Bouaziz-Borgi L, Remy MG, Nguyen P. Utility of thrombin generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations, and protein S deficiency. Clinical Chemistry 2006; 52(4): 665-70. (2006: Impact factor 5.454) Impact factor 7.905 rang A

ACL79     Cochery-Nouvellon E, Vitry F, Cornillet-Lefebvre P, Hézard N, Gillot L, Nguyen P. Interleukin-10 promoter polymorphism and venous thrombosis: A case-control study. Thromb Haemost 2006; 96: 24-8. (2006: Impact factor 2.803)  Impact factor 5.044 rang B

ACL80     Hézard N, Remy MG, Florent B, Nguyen P. Reliability of thrombin generation assay on frozen-thawed platelet-rich plasma: a reply. Clin Chem 2006; 52(11): 2127-8. (2006: Impact factor 5.454) Impact factor 7.905 rang A

ACL81    Bouaziz-Borgi L, Nguyen P, Hezard N, Musharrafieh U, Almawi WY, Mahjoub T. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms. Exp Mol Pathol 2007; 83: 480-3. (2007: Impact factor 1.377 rang D) Impact factor 2.425 rang C

ACL82     Mechiche H, Nguyen P. IL-4 modulates tissue factor expression by human B lymphocytes in response to phorbol myristate acetate. Thrombosis and Haemostasis 2007; 97(1) : 158-9.(2007 Impact factor 3.501 rang C)  Impact factor 5.044 rang B

ACL83     Hézard N, Bouaziz-Borgi L, Remy MG, Florent B, Nguyen P. Protein C deficiency screening using a thrombin-generation assay. Thrombosis and Haemostasis 2007; 97(1): 165-6.(2007 Impact factor 3.501 rang C)  Impact factor 5.044 rang B

ACL84     Poitevin S, Cochery-Nouvellon E, Dupont A, Nguyen P. Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticules. Thrombosis and Haemostasis 2007; 97(4): 598-607(2007 Impact factor 3.501 rang C) Impact factor 5.044 rang B

ACL85     Szymezak J, Houdant N, Toupance O, Brandt B, Nguyen P. Thrombose et transplantation rénale : peut-on prévenir la thrombose veineuse du rein transplanté ? STV 2007 ; 7. Impact factor 0.029

ACL86     Hezard N, Simon G, Macé C, Jallu V, Kaplan C, Nguyen P. Is flow cytometry accurate enough to screen platelet autoantibodies ? Transfusion 2008; 48:513-8. (2008 Impact factor 3.475 rang C) Impact factor 3.217rang C

ACL87     Guyot E, Carillion A, Poli-Mérol ML, Ferrand I, Chauvet P, Nguyen P, Malinovsky JM. Use of rFVIIa in two children presenting major bleeding not controlled by the usual treatments before emergent surgery. Pediatr anesthes 2008; 18: 1226-8. (2008 Impact factor 1.575 rang C)   Impact factor 2.1 rang C

ACL88     Poitevin S, Garnotel R, Antonicelli F, Gillery P, Nguyen P. Type I collagen induces tissue factor expression and matrix metalloproteinase 9 production in human primary monocytes through a redox-sensitive pathway. Thrombosis and Haemostasis 2008; 6:1586-1594.(2008 Impact factor 3.808 rang B)  Impact factor 5.044 rang B

ACL89     Murat O, Durand E, Delépine G, Nguyen P, Malinovski JM. Accident ischémique médullaire associé à l’arrêt du clopidogrel chez une patiente artéritique.Ann Fr Anesth Reanim 2008 ; 27 :335-7. (2008 Impact factor 0.793  rang E)  Impact factor 0.839 rang E

ACL90     Cochery-Nouvellon E, Nguyen P, Attaoua R, Cornillet-Lefebvre P, Mercier E, Vitry F, Gris JC. Interleukin 10 Gene-Promoter Polymorphisms in Women with Pregnancy Loss: Preferential Association with Embryonic Wastage. Biol Reprod 2009.(2009 Impact factor 3.3 rang B)  Impact factor 4.009 rang A

ACL91    Ripert T, Menard J, Schopen Y, Nguyen P, Pieu P, Brandt B, Staerman F. Anticoagulation after renal transplantation a multicenter survery on clinical practice. Prog Urol 2009; 186-91(2009 Impact factor 0.611 rang E) Impact factor 0.578 rang E

ACL92     Elalamy I, Tardy-Poncet B, Mulot A, De Maistre E, Pouplard C, Nguyen P, et al. Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia. Thromb Res. 2009; 124:554-9. (2009 Impact factor 2.406 rang C) Impact factor 2.44 rang C

ACL93     Poitevin S, Ben Hadj Kalifa Kechiche S, Mace C, Nguyen P. IL-10 inhibits apoptosis and microvesiculation of human monocytes. J Thromb Haemost 2009; 7:1241-3. (2009 Impact factor 6.069 rang B). Impact factor 5.731 rang A

ACL94     Ripert T, Menard J, Schoepen Y, Nguyen P, Rieu P, Staerman F. Preventing graft thrombosis after renal transplantation: a multicenter survey of clinical practice. Transplant Proc 2009; 41:4193-6. (2009 Impact factor 0.994 rang D)  Impact factor 1.005 rang E

ACL95     Capiod JC, Tournois C, Vitry F, Sevestre MA, Daliphard S, Reix T, Nguyen P. Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product. Vox Sang 2009; 96:256-65. (2009 Impact factor 2.585 rang C)  Impact factor 2.856 rang C

ACL96     Metz D, Hézard N, Duval S, Tassan-Mangina S, Deschildre A, Brasselet C, Nguyen P. Resistance aux antiagregants plaquettaires: le point de vue du cardiologue. J Mal Vasc 2009; 34:26-33. (2009 Impact factor 0.439 rang E)  Impact factor 0.543 rang E

ACL97     Goeldel AL, Cornillet-Lefebvre P, Durlach A, Birembault P, Bernard P, Nguyen P, et al. T-cell receptor gamma gene rearrangement in cuteanous T-cell lymphoma: comparative study of polymerase chain reaction with denaturing gradient gel electrophoresis and GeneScan analysis. Br J Dermatol 2010; 162:822-9. (2010 Impact factor 4.353 rang A) Impact factor 3.666 rang B

ACL98     Delavenne X, Zufferey P, Baylot D, Nguyen P, Borg JY, Fontenay M, Deygas B, Mismetti P, Laporte S. GETHCAM Study Group; POP-A-RIX Investigators. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost. 2010; 104:252-60. (2010 Impact factor 4.701 rang B) Impact factor 5.044 rang B

ACL99     Cuccuini W, Poitevin S, Poitevin G, Dignat-George F, Cornillet-Lefebvre P, Sabatier F, Nguyen P. Tissue factor up-regulation in proinflammatory conditions confers thrombin generation capacity to endothelial colony-forming cells without influencing non-coagulant properties in vitro. J Thromb Haemost. 2010; 8:2042-52. (2010 Impact factor 5.439 rang B)  Impact factor 5.731 rang A

ACL100     Ben-Hadj-Khalifa-Kechiche S, Hezard N, Poitevin S, Remy MG, Florent B, Mahjoub T, Nguyen P. Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles. J Thromb Thrombolysis. 2010; 30:412-8. (2010 Impact factor 1.539 rang D)  Impact factor 1.476 rang D

ACL101     Ben-Hadj-Khalifa S, Hézard N, Almawi WY, Remy MG, Florent B, Mahjoub T, Nguyen P. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011; 22:369-73. Impact factor 1.238 rang E

ACL102     Ben-Hadj-Khalifa S, Hézard N, Almawi WY, Lakbakbi S, Macé C, Cornillet-Lefebvre P, Mahjoub T, Nguyen P. IL-10 modulates fondaparinux inhibition of monocyte-induced thrombin generation. J Thromb Thrombolysis. 2011; 32(3):311-7. Impact factor 1.476 rang D

ACL103     Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P;Working Group on Perioperative Haemostasis;French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperatives Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011; 104(12):669-76. Impact factor 1.513 rang D

ACL104     Bezier M, Perceau G, Reguiai Z, Remy-Leroux V, Tchen T, Durlach A, et al. Ulcères de jambe nécrotiques induits par les anti-vitamines K :à propos de cinq cas. Ann Dermatol Venereol 2011 ; 138 :657-63. Impact factor 0.716 rang E

ACL105     Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Marinoli JL;Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012; 107(2):379-87. Impact factor 6.094 rang A

ACL106     Pouplard C, Cornillet-Lefebvre P, Attaoua R, Leroux D, Lecocq-Lafon C, Rollin J, Grigorescu F, Nguyen P, Gruel Y. Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. Thromb Res. 2012; 129(4):465-9. Impact factor 3.133 rang C
ACL107     Delavenne X, Zufferey P, Nguyen P, Rosencher N, Samama CM, Bazzoli C, Mismetti P, Laporte S. Pharmacokinetics of fondiparinux 1,5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. Eur J Clin Pharmacol. 2012; 25. Impact factor 2.741 rang C
ACL108     Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S. Venous thromboembolism prevention with fondaparinux 1,5 mg in renally impaired patients undergoing major orthopaedic surgery. A real world, prospective, multicentre, cohort study. Throm Haemost. 2012;107(6):1151-1160. Impact factor 6.094  rang A

ACL109     Ben-Hadj-Khalifa S, Nguyen P, Mahjoub T, Hezard N. Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model. Eur Cytokine Netw 2012. Impact factor 1.896 rang E.

ACL110     Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sié P. Questions-réponses sur l’utilisation du rivaroxaban pour le traitement de la maladie thromboembolique veineuse. Journal des Maladies Vasculaires 2012;37(6) :300-10. Impact factor 0.235 rang E

ACL111 François-Fiquet C, Poli-Merol ML, Nguyen P, Landais E, Gaillard D, Doco-Fenzy M.  Role of angiogenesis-related genes in cleft lip/palate: review of the literature. International Journal Pediatric Otorhinolaryngology 2014;78(10): 1579-1585. Impact factor 1.186, rang D

ACL112 Kawecki C, Hézard N, Bocquet O, Poitevin G, Rabenoelina F, Kauskot A, Duca L., Blaise S, Romier B, Martiny L, Nguyen P, Debelle L, Maurice P. Elastin-Derived Peptides Are New Regulators of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(12):  2570-2578. Impact Factor 6, rang A

ACL113 Krummel T, Scheidt E, Borni-Duval C, Bazin D, Lefebvre F, Nguyen P,   Hannedouche T. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? Nephrology Dialysis Transplantation 2014; 29 (4):  906-913. Impact Factor 3.577, rang B

ACL114 de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hézard N, Trossaërt  M. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thrombosis  Haemostasis  2014;112: 825-830, Impact factor 4.984, rang B

ACL115 Tournois C, Pignon B, Sevestre MA, Djerada Z, Capiod JC, Poitevin G, Delloup AM, Nguyen P. Critical limb ischemia: thrombogenic evaluation of two autologous cell therapy products and biologic profile in treated patients.Transfusion 2015;55(11): 2692-2701. Impact factor 3.225, rang C

ACL116 Lakbakbi S, Debrumetz A, Rieu P. Nguyen P. Human Neutrophils Support Thrombin Generation in Peritonitis. Peritoneal Dialysis International 2015;35(5): 599-602. Impact Factor 1.527, rang D

ACL117 Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, Morel J, Wynckel A, Grunebaum L, Villacorta-Torres J, Grosjean S, de Maistre E. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Critical Care. 2015;11(19): 396. Impact Factor 4.476, rang B

ACL118 Kessler M, Moureau F, Nguyen P. Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach. Seminars in Dialysis 2015;28(5): 474-489, Impact factor 1.745, rang D

ACL119 Faraoni D, Levy JH, Albaladejo P ,Samama CM. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Critical Care 2015;19: 203. Impact factor 4.476, rang B

ACL120 Zuily S, Rat AC, Regnault V, Kaminsky P, Mismetti P, Ninet J, Baillet N, Magy-Bertrand N, Pasquali JL, Lambert M, Pasquier E, Lorcerie B, Lecompte T, Guillemin F, Wahl D TAC(I)T investigators. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus 2015;24(11): 1161-1168. Impact factor 2.197, rang D

ACL121 Coscarella M, Viart L, Nguyen P, Saint F. [New oral anticoagulants and prostate biopsy: Which usual precaution should we use?]. Progrès en Urologie 2015; 25(9): 510-515. Impact factor 0.658, rang E

ACL122 Guillou S, Tamareille S, Giraud S, Poitevin G, Prunier-Mirebeau D, Nguyen P, Prunier F, Macchi L. Fondaparinux upregulates thrombomodulin and the endothelial protein C receptor during early-stage reperfusion in a rat model of myocardial infarction. Thrombosis Research. 2016; 141: 98-103. Impact factor 2.447, rang D

ACL123    Lakbakbi, S., Debrumetz, A., Terryn, C., Szymezak, J., Rieu, P., Nguyen, P. 2016 Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity. Thrombosis Research 144, pp.218-223. IF 2.32, rg D

ACL124     Veyradier, A., Boisseau, P., Fressinaud, E., Caron, C., Ternisien, C., Giraud, M., Zawadzki, C., Trossaert, M., Itzhar-Baïkian, N., Dreyfus, M., d'Oiron, R., Borel-Derlon, A., Susen, S., Bezieau, S., Denis, CV., Goudemand, J; French Reference Center for von Willebrand disease. 2016 A Laboratory Phenotype/Genotype Correlation of 1167 French Patients from 670 Families with von Willebrand Disease: A New Epidemiologic Picture. Medicine (Baltimore) 95(11), pp.e3038.  IF 1.206, rg D

ACL 125  Rey, JB., Jovenin, N., Kreit, P., Sicard, J., Parent, D., Hettler, D., Nguyen, P.,Ducrocq, JL. 2016 Venous thromboembolism: What pharmacists know? What do they need? Journal of Oncology Pharmacy Practice 22(1), pp.135-141. IF nc

ACL 126 Maufus, M., Antoinette Sevestre-Pietri, M., Sessa, C., Pignon, B., Egelhofer, H., Dupas, S., Nguyen, P., Genty, C., Pernod, G 2017 Critical limb ischaemia and the response to bone marrow-derived cell therapy according to tcPO2 measurement. Vasa 46(1), pp.23-28. IF 1.222, rg E

ACL 127 Tournois, C., Pignon, B., Sevestre, MA., Al-Rifai, R., Creuza, V., Poitevin, G., François, C., Nguyen, P. 2017 Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products. Cytotherapy 19(2), pp.299-310. IF 3.625, rg C

ACL 128  Nicol, P., Bernard, P., Nguyen, P., Durlach, A., Perceau, G. 2017 [Retrospective study of hypertensive leg ulcers at Reims University Hospital: Epidemiological, clinical, disease progression data, effects of vitamin K antagonists]. Annales de Dermatologie et de Vénéréologie 144(1), pp.37-44. IF 0.584, rg E

ACL 129     Meunier, S., d'oiron, R., Chambost, H., Dolimier, E., Guillet, B.; ORTHem 15-25 Study Group. 2017 Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25). Thrombosis Research 151, pp.17-22. IF 2.32, rg D

ACL 130 Francois-Fiquet, C., Poli-Merol, ML., Tournois, C., Djerada, Z., Cornillet-Lefebvre, P., Guillard, T. Doco Fenzy, M. Nguyen, P. 2017  A new in vivo model to analyze the expression of angiogenic genes in cleft lip borders. British Journal of Oral & Maxillofacial Surgery. [Epub ahead of print]. IF 1.076, rg D